Drug Search Results
More Filters [+]

FPP-003

Alternative Names: fpp-003, fpp003, fpp 003
Latest Update: 2023-04-17
Latest Update Note: Clinical Trial Update

Product Description

FPP003 is antibody-inducing peptide targeting interleukin-17A (IL-17A) under joint development with Osaka University and Sumitomo Dainippon Pharma.

Mechanisms of Action: IL17 Inducer

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: FunPep Co
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for FPP-003

Countries in Clinic: Australia

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ACTRN12619000599178

P2

Completed

Psoriasis

2022-06-06

Recent News Events

Date

Type

Title